AT 342

Drug Profile

AT 342

Alternative Names: AAV-gene-therapy-Audentes; AAV-UGT1A1; AT-342; Crigler-Najjar-Syndrome-gene-therapy-Audentes

Latest Information Update: 21 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Audentes Therapeutics
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hyperbilirubinaemia
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Hyperbilirubinaemia

Most Recent Events

  • 08 Sep 2017 Audentes Therapeutics initiates enrolment in the phase I/II VALENS trial in Hyperbilirubinaemia in USA (IV) (NCT03223194)
  • 31 Aug 2017 Phase-I/II clinical trials in Hyperbilirubinaemia in USA (IV) (Audentes Therapeutics pipeline, August 2017)
  • 01 Feb 2017 Preclinical trials in Hyperbilirubinaemia in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top